Needham lowered the firm’s price target on Revance to $40 from $44 after its wider than expected Q2 loss but keeps a Buy rating on the shares. Daxxify launch trajectory should pick up steam in the second half of the year, driven by the recent sales force expansion and the June launch of the “BreakUpWithBotox” DTC campaign, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RVNC:
- 3 Best Stocks to Buy Now, 8/9/2023, According to Top Analysts
- Revance price target lowered to $41 from $48 at H.C. Wainwright
- Revance sees FY23 adjusted operating expenses $320M-$340M
- Revance Therapeutics reports Q2 EPS (80c), consensus (78c)
- Cantor biotech/biopharma analysts to hold analyst/industry conference call
